Showing results (1-10 of 429) with videos related to
Sort By:
Pageof 43
Expert Opinion on Biological Therapy|November 24, 2007
Recent findings into the potential of gene therapy to reverse heart failureSven T Pleger, Patrick Most, Walter J KochJournal of Cardiac Failure|July 3, 2007
Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapySven T Pleger, Matthieu Boucher, Patrick Most, et al.American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|April 27, 2007
S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevancePatrick Most, Andrew Remppis, Sven T Pleger, et al.Circulation Research|August 31, 2013
Heart failure gene therapy: the path to clinical practiceSven T Pleger, Henriette Brinks, Julia Ritterhoff, et al.Clinical and Translational Science|May 7, 2010
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesisMatthieu Boucher, Stéphanie Pesant, Yong Hong Lei, et al.Molecular and Cellular Biology|April 18, 2007
Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytesMelanie Boerries, Patrick Most, Jonathan R Gledhill, et al.Clinical and Translational Science|May 7, 2010
BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cellsBrent R Degeorge, Marc Rosenberg, Volker Eckstein, et al.Molecular and Cellular Biochemistry|November 5, 2004
Genetic and phenotypic targeting of beta-adrenergic signaling in heart failureWalter J KochFuture Cardiology|April 18, 2009
Heart failure gene therapy: closer to reality. Professor Walter Koch speaks to Christine Forder, commissioning editorWalter J KochMolecular and Cellular Biochemistry|August 14, 2016
Genetic and phenotypic targeting of β-adrenergic signaling in heart failureWalter J KochPageof 43